NotizieAssistito da IA

China Accepts Telix NDA For Illuccix PSMA-PET Prostate Cancer Imaging

Telix secures NDA acceptance in China for Illuccix, marking a major step toward expanding PSMA-PET imaging in prostate cancer care.

Di Vaibhavi M.

Esperto del settore (B.Pharm) · Pharma Now

20 gen 20262 min di lettura

Condividi Aggiungi come fonte preferita

China Accepts Telix NDA For Illuccix PSMA-PET Prostate Cancer Imaging

Giornalismo assistito da IA

Reviewed by Vaibhavi M., Esperto del settore (B.Pharm) · Pharma Now

Telix Pharmaceuticals has announced that China’s National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has accepted the New Drug Application (NDA) for TLX591-Px (Illuccix®), a kit used to prepare ^68Ga-PSMA-11 for prostate cancer imaging. Illuccix is Telix’s lead diagnostic imaging agent for prostate cancer and represents a key step in expanding access to PSMA-PET imaging in China.

ArgomentiNotizie

Written by

Vaibhavi M.

Esperto del settore (B.Pharm) · Pharma Now

Reporting on the science, business and regulation shaping the pharmaceutical industry.